Cizzle Biotechnology announces North American licensing deal to launch revolutionary early lung cancer blood test in 2025

Contributed by: PR Newswire

Tags

Cizzle-Licensing-NA

More Like This

CIZZLE BIOTECHNOLOGY ANNOUNCES GROUNDBREAKING COLLABORATION WITH MOFFITT CANCER CENTER TO ADVANCE EARLY-STAGE LUNG CANCER DETECTION

Oxford Cancer Analytics Raises USD$11M in Series A Funding to Transform Early Lung Cancer Detection and Enable Curative Treatments

PR Newswire associated0

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

PR Newswire associated0

Zedsen partners with Imperial College Healthcare NHS Trust to clinically validate its novel non-invasive sensing technology

BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial

PR Newswire associated0

'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology

PR Newswire associated0

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

PR Newswire associated0

Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease